Current Ebola Virus Vaccine Progress.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
4
1
2019
medline:
17
7
2019
entrez:
4
1
2019
Statut:
ppublish
Résumé
Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.
Identifiants
pubmed: 30604389
doi: 10.1007/s40259-018-0329-7
pii: 10.1007/s40259-018-0329-7
doi:
Substances chimiques
Ebola Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-14Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : UC7 AI094660